SCHEMBL5700502

SCHEMBL5700502

Cc1ccc(S(=O)(=O)c2cc(Cl)ccn2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.50
▸ PKM P14618 1/20 0.50
▸ GAA P10253 1/20 0.48
▸ HSP90AA1 P07900 2/20 0.46
▸ COMT P21964 2/20 0.46
▸ HPGD P15428 1/20 0.45
▸ KMT2A Q03164 3/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ CXCR5 P32302 1/20 0.44
▸ APLNR P35414 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ CCR6 P51684 1/20 0.44
▸ GFER P55789 1/20 0.44
▸ AKR1B1 P15121 1/20 0.44
▸ RAPGEF4 Q8WZA2 1/20 0.43
▸ HTR6 P50406 2/20 0.42
▸ NLRP3 Q96P20 1/20 0.42
▸ MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5700395 0.80 GAA (0.48) KDM4EPKMGAAHSP90AA1COMT
SCHEMBL5700365 0.80 GAA (0.48) KDM4EPKMGAAHSP90AA1COMT
SCHEMBL7459868 0.74 KDM4E (0.69) KDM4EPKMGAAHSP90AA1COMT
SCHEMBL10661374 0.73 KMT2A (0.47) KDM4EPKMGAAHSP90AA1COMT
SCHEMBL1573581 0.72 ALDH1A1 (0.52) KDM4EPKMHPGDKMT2AALDH1A1
SCHEMBL7566063 0.72 GAA (0.52) KDM4EPKMGAAHSP90AA1KMT2A
SCHEMBL21572393 0.72 KDM4E (0.39) KDM4EPKMHPGDALDH1A1HTT
SCHEMBL28446740 0.72 HSP90AA1 (0.46) KDM4EGAAHSP90AA1HPGDKMT2A
SCHEMBL811061 0.72 ALDH1A1 (0.76) KDM4EPKMGAAHPGDKMT2A
SCHEMBL845525 0.72 ALDH1A1 (0.44) KDM4EPKMALDH1A1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1270582-B1 TRIPHENYLPHOSPHINE DERIVATIVES, PALLADIUM OR NICKEL COMPLEXES THEREOF, AND PROCESS FOR PREPARING BIARYL DERIVATIVES MITSUBISHI RAYON CO (JP) 2006-08-30 — — EP disclosed
US-6693210-B2 USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS MITSUBISHI RAYON CO., LTD. (JP) 2004-02-17 — — US disclosed
US-20030065208-A1 Using palladium, nickel phosphine complex as catalysts MITSUBISHI RAYON CO., LTD. (JP) 2003-04-03 — — US disclosed
EP-1270582-A1 TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE Mitsubishi Rayon Co., Ltd. (JP) 2003-01-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065208-A1 Using palladium, nickel phosphine complex as catalysts PDCD1LG2, PIK3CA, PDCD1 KDM4E 2983/4885PKM 2994/4885GAA 3051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback